TENOFOVIR DISOPROXIL HEMI-FUMARIC ACID CO-CRYSTAL

摘要

The present invention provides a novel crystalline form of Tenofovir diso proxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in parti cular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine , Ritonavir and/or TMC114.